1. Introduction {#sec1}
===============

The beneficial effects of cardiac resynchronization therapy (CRT) have been well established in patients with congestive heart failure (CHF) who remain in New York Heart Association (NYHA) classes II--IV, despite the maintenance on guidelines directed optimal medical treatment and have a wide QRS (≥130 ms) and reduced left ventricular ejection fraction (LVEF) (≤35%).[@bib1], [@bib2] Subgroup analyses of large trials suggest that the benefits are more established in patients with wider QRS durations and/or left bundle branch block (LBBB),[@bib3], [@bib4], [@bib5] and this has been recognized in current guidelines.[@bib6], [@bib7] Recently, it has been suggested that CRT may also be beneficial in patients with a moderately impaired LV function (LVEF \> 35%)[@bib8], [@bib9], [@bib10] by results of post hoc subgroup analysis from the PROSPECT,[@bib8] MADIT-CRT,[@bib9] and REVERSE[@bib10] trials. Many patients with NYHA II--IV CHF with a less reduced LVEF (35--45%) are refractory to optimized medical treatment and remain at high risk of morbidity and mortality, yet with few established other treatment options, and their prognosis is worse in the presence of prolonged QRS complex, especially LBBB.[@bib11], [@bib12] We aimed with this study to prospectively evaluate the effects of CRT in optimally treated patients with NYHA Classes II--IV CHF, LVEF of 36--45%, and LBBB and whether these outcomes are associated with structural changes in cardiac chambers dimensions and biochemical parameters indicating improved HF status.

2. Methods {#sec2}
==========

2.1. Patient selection {#sec2.1}
----------------------

After approval by the 'ethical committee' of Ain-Shams University and the patients\' consents, we prospectively included patients with stable symptomatic HF, NYHA class II/IV, despite maximal tolerated medical treatment for at least 6 months, moderate impairment of LV systolic function, with a LVEF = 36--45%, sinus rhythm with a complete LBBB and a QRS duration ≥130 ms, and no history of ventricular arrhythmias or indication for an implantable cardioverter defibrillator (ICD) for secondary prevention during the period from July 2016 to March 2018.

2.2. Study design {#sec2.2}
-----------------

The study was a single-center, prospective pilot study where all patients were recruited, underwent device implantation, and followed up at the same center.

At baseline, all patients were subjected to thorough history analysis and clinical examination to define their functional class, quality of life (QOL) assessment, 6-min walk distance (6 MWD) test, 12-lead surface electrocardiogram (ECG), and serum plasma level assessment of N-terminal pro b-type natriuretic peptide (NT-Pro BNP).[@bib13], [@bib14]

A transthoracic echocardiographic assessment (TTE) was performed at baseline using a Vivid 7 machine with an M4S matrix sector array probe with a frequency range of 1.5--3.6 MHz (GE Vingmed Ultrasound, Horten, Norway) with the machine-integrated ECG recording connected. The echocardiographic measurements were performed in concordance with the recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging[@bib15] and included LV EF (%) in 2D using Modified Simpson\'s method of discs in the apical four- and two-chamber views. Also left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) using M-mode echocardiography from the parasternal short-axis view at the level of the papillary muscles were measured. The left atrial volume index (LAVI) was also measured in mL/m^2^ using the Simpson\'s method of discs in both apical four- and three-chamber views.

2.3. Device therapy {#sec2.3}
-------------------

All patients underwent a CRT-P device implantation; we used commercially available transvenous leads and devices. Standard implantation technique was used with an emphasis on placing the left ventricular lead to the lateral or posterolateral wall of the left ventricle whenever possible. All patients had implanted standard bipolar LV leads. Patients with inaccessible lateral, posterior, or posterolateral vein tributaries of the coronary sinus as well as patients with inadequate thresholds or inappropriate phrenic nerve stimulation were excluded from the study to avoid effects of several cofounding factors on outcome. The atria to ventricle delay and the ventricle to ventricle delays were optimized immediately after implantation using TTE.[@bib16]

2.4. Follow-up evaluation {#sec2.4}
-------------------------

Patients were seen at follow up visits at 4 weeks, 12 weeks, and 24 weeks after implantation. At each follow-up visit, clinical assessment was performed including the following: NYHA class, QOL evaluation using the Minnesota living with heart failure questionnaire,[@bib17] 6MWD test, QRS duration in milliseconds on 12-lead surface ECG, TTE evaluating the same parameters assessed at baseline studies, and serum level of NT-proBNP in pg/m.

CRT response was defined as an improvement of NYHA class by one class, in addition to decrease in LV end systolic volume (ESV) of ≥15% and/or absolute increase of 5% in LVEF at 6-month visit.[@bib18], [@bib19], [@bib20]

2.5. Statistical analysis {#sec2.5}
-------------------------

Analysis of data was performed using SPSS, version 22.0, SPSS Inc, Chicago, IL. Categorical variables were expressed as numbers or percentages. Description of quantitative variables was obtained as mean ± standard deviation and range. Description of qualitative variables was obtained in the form of frequency and percentage. A quantitative difference in mean values was tested with the Student *t*-test of two independent samples and expressed as *t*-value and *p*-value. Paired *t*-test was used to compare quantitative data in the same group at different intervals. Chi-square and Fisher exact tests for categorical variables are used.

Two-tailed *p* values are presented, with \<0.05 designated as statistically significant.

3. Results {#sec3}
==========

Twenty-three patients have been included in our study and formed the basis of the statistical analyses.

3.1. Baseline demographic data {#sec3.1}
------------------------------

The baseline demographic and clinical characteristics of the studied population are listed in ([Table 1](#tbl1){ref-type="table"}).Table 1Baseline demographic and clinical characteristics of the studied group.Table 1ParameterResultAge (Years): mean ± SD61.65 ± 10.54Gender Male, *n* (%)14 (60%) Female, *n* (%)9 (39%)Etiology of heart failure ICM, *n* (%)10 (43.5%) DCM, *n* (%)13 (56.5%)Risk factors and comorbidities DM, *n* (%)13 (56.5%) Hypertension, *n* (%)15 (65.2%) Obesity, *n* (%)3 (13%) Renal impairment, *n* (%)3 (13%) COPD, *n* (%)5 (21.7%) CLD, *n* (%)3 (13%)Drug treatment ACEIs/ARBs, *n* (%)20 (87%) β blockers, *n* (%)19 (83%) Loop diuretics, *n* (%)21 (91.3%) MRAs, *n* (%)18 (78.3%) Digitalis, *n* (%)16 (70%)NYHA class II, *n* (%)3 (13%) III, *n* (%)12 (52%) IV, *n* (%)8 (35%)QOL: mean ± SD73.6 ± 8.16 MWD (m): mean ± SD145.7 ± 20.1QRS duration (ms): mean ± SD164.4 ± 13.2LVEDD (mm): mean ± SD68.95 ± 5.05LVESD (mm): mean ± SD54.1 ± 4.48LVEF (%): mean ± SD40.35 ± 2.77LAVI (mL/m^2^): mean ± SD42.95 ± 3.3NT-ProBNP (pg/mL): mean ± SD1025.6 ± 363.1[^1]

3.2. Outcome measures {#sec3.2}
---------------------

The clinical response of the patients in the study after 6 months from implantation (changes in NYHA functional class, QOL, and 6 MWD), electrocardiographic response (changes in QRS duration), echocardiographic response (changes in LVEDD, LVESD, LVEF, and LAVI), and biochemical response (changes in serum level of NT-ProBNP) are listed in ([Table 2](#tbl2){ref-type="table"}).Table 2Outcome of different parameters after 6 months of CRT implantation.Table 2ParameterBaselineAfter CRT*p*-valueNYHA class I, *n* (%)0 (0%)3 (13%)\<0.0001 II, *n* (%)3 (13%)13 (57%)\<0.0001 III, *n* (%)12 (52%)5 (22%)\<0.0001 IV, *n* (%)8 (35%)2 (8%)\<0.0001QOL: mean ± SD73.6 ± 8.154.45 ± 8.34\<0.00016 MWD (m): mean ± SD145.7 ± 20.1219.5 ± 42.25\<0.0001QRS duration (ms): mean ± SD164.4 ± 13.2126.4 ± 13.69\<0.0001LVEDD (mm): mean ± SD68.95 ± 5.0562.8 ± 4.470.00022LVESD (mm): mean ± SD54.1 ± 4.4846.5 ± 4.09\<0.0001LVEF (%): mean ± SD40.35 ± 2.7748.3 ± 4.16\<0.0001LAVI (mL/m^2^): mean ± SD42.95 ± 3.337.8 ± 3.02\<0.0001NT-ProBNP (pg/mL): mean ± SD1025.6 ± 363.1594.9 ± 263.540.00012[^2]

Patients\' clinical response showed significant improvement of all parameters. The NYHA functional class significantly improved after CRT-P (*p* \< 0.0001). This was also associated with significant improvement in QOL (from 73.6 ± 8.1 to 54.45 ± 8.34, *p* \< 0.0001) and 6 MWD, which significantly increased, from 145.7 ± 20.1 m to 219.5 ± 42.25 m (*p* \< 0.0001).

Mean QRS duration showed significant shortening after CRT, decreasing from 164.4 ± 13.2 ms to 126.4 ± 13.69 ms (*p* \< 0.0001).

The echocardiographic examination showed reduction in both LVEDD (from 68.95 ± 5.05 mm to 62.8 ± 4.47 mm, *p* = 0.0002) and LVESD (from 54.1 ± 4.48 mm to 46.5 ± 4.09 mm, *p* \< 0.0001), which was translated into significant increase in LVEF (from 40.35 ± 2.77 to 48.3 ± 4.16 mm, *p* \< 0.0001). The LA volume was significantly reduced as measured by LAVI (from 42.95 ± 3.3 mL/m^2^ to 37.8 ± 3.02 mL/m^2^, *p* \< 0.0001).

The biochemical response to CRT showed significant improvement in serum levels of the NT-Pro BNP which were reduced from 1025.6 ± 363.1 pg/ml to 594.9 ± 263.54 pg/ml (*p* \< 0.0001).

The echocardiographic response (changes in LVEDD, LVESD, LVEF, and LAVI), and biochemical response (changes in serum level of NT-Pro BNP) were evaluated after 4 weeks, 12 weeks, and 24 weeks after implantation and the changes in these parameters are shown in ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}).Fig. 1Echocardiographic response during the first 6 months after CRT. CRT, cardiac resynchronization therapy; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index.Fig. 1Fig. 2Biochemical response during the first 6 months after CRT. CRT, cardiac resynchronization therapy; NT-ProBNP, N-terminal pro b-type natriuretic peptide.Fig. 2

3.3. CRT response {#sec3.3}
-----------------

According to the predefined measures for response to CRT, only 2 patients were nonresponders. Both were male patients, one with DCM and the other with ICM, with a mean LVEF = 42.57 ± 2.31 and a mean QRS duration = 128.2 ± 11.49.

There was no statistically significant difference in CRT response based on the etiology of cardiomyopathy in the studied population. Both patients with dilated cardiomyopathy and ischemic cardiomyopathy showed similar response to CRT at the end of the study follow-up ([Table 3](#tbl3){ref-type="table"}).Table 3Response to CRT according to the etiology of cardiomyopathy.Table 3ParameterDCMICM*p*-valueBaselineAfter CRTBaselineAfter CRTNYHA class I, *n* (%)0 (0%)2 (15.4%)0 (0%)1 (10%)0.134 II, *n* (%)2 (15.4%)7 (53.8%)1 (10%)6 (60%)0.716 III, *n* (%)6 (46.1%)3 (23.1%)6 (60%)2 (20%)0.35 IV, *n* (%)5 (38.5%)1 (7.7%)3 (30%)1 (10%)0.99QOL: mean ± SD72.5 ± 2.352.8 ± 6.674.2 ± 3.056.1 ± 8.50.3296 MWD (m): mean ± SD146.9 ± 5.8223.9 ± 43.1143.6 ± 6.9215.1 ± 41.40.625QRS duration (ms): mean ± SD167.2 ± 4.7130.2 ± 14.1162.8 ± 2.6122.7 ± 13.20.205LVEDD (mm): mean ± SD69.2 ± 3.163.4 ± 4.567.6 ± 4.362.1 ± 4.40.495LVESD (mm): mean ± SD55.2 ± 3.847.4 ± 4.154.3 ± 5.745.6 ± 3.90.296LVEF (%): mean ± SD40.8 ± 3.448.8 ± 4.640.2 ± 4.147.8 ± 3.90.579LAVI (mL/m^2^): mean ± SD43.2 ± 4.138.4 ± 3.542.6 ± 2.837.2 ± 2.80.371NT-ProBNP (pg/mL): mean ± SD1037.6 ± 387.2612.7 ± 271.41019.4 ± 346.5577.1 ± 255.60.751[^3]

4. Discussion {#sec4}
=============

CRT is an established standard of care for advanced systolic HF patients with evidence for ventricular dyssynchrony as represented by QRS duration ≥120 ms.[@bib1], [@bib2] Landmark clinical trials have used LVEF ≤35% as entry criteria, making this cutoff value as a major determinant for patient eligibility for CRT in clinical practice.[@bib1], [@bib2]

However, there are several considerations that deserve closer consideration of the role of LVEF in patient selection for CRT. Selection of LVEF ≤35% as the entry criterion for HF clinical trials is based on a higher risk of adverse outcomes, particularly sudden cardiac death.[@bib21], [@bib22]

LVEF is recognized as a risk predictor for morbidity and mortality in HF patients. While the risk of hospitalization and/or death declines as LVEF increases, an LVEF in the range of 36%--45% still confers a significant risk of adverse outcomes, whereas a higher LVEF does not further contribute to mortality.[@bib21], [@bib22], [@bib23] Although excluded from CRT according to current guidelines, there are HF patients with LVEF \>35% who may benefit from therapy. Clearly, the disease burden due to HF with preserved systolic function is significant, as nearly 50% of hospitalized patients with HF have a measured LVEF \>35%.[@bib24], [@bib25]

Taken together, these facts illustrate the need for therapies in this increasing population with mildly reduced LVEF. The present study was conducted to evaluate the different effects (clinical, structural and biochemical) of CRT in a cohort of patients with symptomatic CHF, LBBB, and mildly reduced LV function (LVEF 36--45%).

Over a period of 21 months, 23 eligible patients have been subjected to CRT-P implantation and were followed up for a period of 6 months to evaluate the clinical, echocardiographic, and biochemical response to CRT. Fung et al[@bib26] have included 15 patients with NYHA class III and LBBB, with an LVEF \>35% and \<45%. They followed the patients for 3 months for both standard HF assessment and echocardiographic examination. More recently, Linde et al have designed a prospective, randomized, controlled, double-blinded study to evaluate CRT-P in NYHA II--III HF patients with LBBB and with LVEF of 36%--50% and no previous pacing or ICD. The primary endpoint was a composite of time to first HF event or death. The MIRACLE EF study was stopped for enrollment futility after 13 months and enrolling only 44 patients.[@bib27]

The present study showed significant improvement in HF symptoms and NYHA functional class. Most patients have improved at least one NYHA class. Furthermore, standard HF assessment using the Minnesota living with heart failure questionnaire and 6 MWD showed significant improvement after CRT (*p* \< 0.0001). Fung et al[@bib26] showed significant improvement in NYHA functional class, whereas other HF assessment parameters (QOL score, 6 MWD, exercise capacity in a metabolic equivalents of task (METS) test) did not show significant improvement after 3 months of follow-up. This could be explained by the small number of patients included in the study and shorter period of follow-up. Foley et al[@bib28] observed similar clinical improvements (NYHA functional class, QOL score, and 6 MWD) in patients with LVEF \>35%, compared with patients with LVEF ≤35%. Results of post-hoc analyses of randomized controlled trials of CRT reported comparable CRT benefits in patients with an LVEF \>35%[@bib8], [@bib9], [@bib10] as in patients with LVEF ≤35%. In a substudy from the PROSPECT trial that included NYHA III--IV HF patients, Chung et al[@bib8] reported similar benefits from CRT regarding the clinical composite response by Packer and reverse remodeling in patients with LVEF \>35% compared to those with LVEF \<35%.

The present study shows significant reduction of LV dimensions and LA volume with an associated significant improvement of LV systolic function, as examined by measurement of LVEF using 2D echocardiography. These changes were maintained over the follow-up period of 6 months with continuous improvement of all these parameters over time since CRT implant (see [Fig. 1](#fig1){ref-type="fig"}). The improvement of LVEF was linear and reached 19.7% increase after 6 months compared with baseline LVEF demonstrating a super-response in this patient cohort who were selected mainly based on wide baseline QRS complex and morphology of LBBB.

Careful analysis of the REVERSE study revealed that almost 24% of patients had LVEF \>30%. After a 24-month follow-up time, CRT in patients with LVEF \>30% resulted in a significant 74% relative risk reduction in time to HF hospitalizations or death compared with 42% in the group with LVEF ≤30%. There were also associated reductions in LV ESV index and LV mass in LVEF \>30% patients, although not to the same extent as in those with LVEF \<30%.[@bib10]

Electrical dyssynchrony is critical for CRT-induced improvements, with previous studies suggesting that response increases with longer intrinsic QRS duration and LBBB morphology.[@bib3], [@bib4] Our patients had wide QRS (164.4 ± 13.2 msec), and all patients had LBBB. Coinciding with these findings, a meta-analysis of 5 randomized trials showed that increasing QRS duration at baseline was an independent predictor for response to CRT.[@bib29] These results indicate that the benefits of CRT may be present for patients with QRS prolongation and mild HF with less severe LV dysfunction than previously studied.

LA enlargement is a marker of both the severity and chronicity of diastolic dysfunction and magnitude of LA pressure elevation in patients with HF.[@bib30] In addition, relationships exist between increased LA size and the incidence of atrial fibrillation and stroke, risk of overall mortality after myocardial infarction, and risk of death and hospitalization in patients with dilated cardiomyopathy.[@bib31] In a recent study, we demonstrated that CRT resulted in significant reduction in LA diameter and maximal and minimal LA volumes (LA Vmax and LA Vmin, respectively). This favorable effect of reverse LA remodeling was limited to the cardiac responders group (i.e., those with significant LV reverse remodeling).[@bib32] In the present study, there is significant reduction in LA volume index after CRT in our patient cohort. The reduction was observed after 4 weeks and was evident at 3 months from CRT implantation (see [Fig. 1](#fig1){ref-type="fig"}). This early significant reduction in atrial volumes at 3 months was also reported by Vural et al[@bib33] to occur simultaneously with LV reverse remodeling; even more early favorable changes in LA volumes were reported only 1 month after CRT implantation and kept going on until at least 6 months after implantation.[@bib34] These findings can be simply explained by the improvement in LV systolic and diastolic functions and filling pressures and consequently resulting in decrease in LA pressures.

Natriuretic peptides (NPs), specifically BNP and NT-pro BNP, have diagnostic and prognostic values in patients with HF.[@bib35], [@bib36] Decreases in BNP during follow-up with various HF therapies are associated with reduced morbidity and mortality outcomes, whereas increasing BNP portends poor patient outcomes.[@bib37], [@bib38], [@bib39], [@bib40]

The present study demonstrated significant reduction of the serum levels of NT pro-BNP after CRT (*p* \< 0.0001). The reduction was well noticed after 4 weeks of CRT implantation and was maintained throughout the 6 months follow up period (see [Fig. 2](#fig2){ref-type="fig"}). The CARE-HF study demonstrated that CRT exerts a remarkable early and sustained reduction in plasma concentrations of NT-pro-BNP levels when compared with pharmacological therapy alone in patients with moderate to severe chronic HF and markers of ventricular dyssynchrony.[@bib39] The early reduction in NT-pro-BNP observed in CARE-HF and in our study probably reflects the acute hemodynamic improvement after CRT. This is translated into reduction in ventricular filling pressure and improved efficiency with subsequent ventricular reverse remodeling. Later, analysis by Fruhwald et al[@bib40] confirmed these observations and demonstrated that CRT resulted in an early and sustained reduction in NT-pro-BNP that was associated with early and progressive improvement in echocardiographic LV parameters. Therefore, NT-pro-BNP may be a useful additional marker of monitoring the effects of CRT especially in early postimplantation period.

Several reports have demonstrated criteria of responder patients to CRT, including female sex, nonischemic etiology of cardiomyopathy, LBBB, and QRS duration ≥150 msec.[@bib7], [@bib41], [@bib42]

The results of our study did not show such significant differences in outcomes among both sexes and patients with ischemic or nonischemic cardiomyopathy, probably because of small sample size, well-selected patients at entry with LBBB, and wide QRS complex \>150 msec (see [Table 3](#tbl3){ref-type="table"}).

5. Conclusions {#sec5}
==============

In this prospective single-center study, symptomatic HF patients on maximal optimized medical treatment who have LBBB and a baseline LVEF 35--45% appeared to derive significant clinical and structural benefit from CRT.

However, before expanding indications for CRT to include patients with less severe LV systolic dysfunction, randomized prospective studies to evaluate the effect of CRT on such important group of HF patients are needed. Furthermore, long-term follow-up is needed to demonstrate morbidity and mortality improvements on top of existing medical therapy in such relatively lower risk HF population.

5.1. Study limitations {#sec5.1}
----------------------

The major limitation of the present study is the small sample size and nonrandomized design. Larger randomized studies with a crossover design would be a more beneficial approach to start examining a potentially new indication for CRT in such an important sector of HF patients.
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[^1]: ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; MRA, mineralocorticoid receptor antagonists; QOL, quality of life; 6 MWD, 6-min walk distance test; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; NT-ProBNP: N-terminal pro b-type natriuretic peptide; SD, standard deviation.

[^2]: QOL, quality of life; 6 MWD, 6-min walk distance test; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; NT-ProBNP, N-terminal pro b-type natriuretic peptide; SD, standard deviation.

[^3]: QOL, quality of life; 6 MWD, 6-min walk distance test; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; NT-ProBNP, N-terminal pro b-type natriuretic peptide; SD, standard deviation.
